Exact Sciences Corporation EXAS reported a net loss of 21 cents in third-quarter 2024 compared with break-even earnings in ...

Exact Sciences (EXAS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong ... been boosted by laboratory service ...

Precision Oncology revenues are likely to have been boosted by laboratory service ... Earnings ESP: Exact Sciences currently has an Earnings ESP of 0.00%. Zacks Rank: EXAS currently has a ...

An advert narrated by Julia Roberts encouraging women to keep their votes a secret from their husbands has triggered fury ...

Liz Cheney, a former high-ranking GOP congresswoman who has endorsed Ms Harris ... with more than 65 million ballots already ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences Corporation EXAS reported a net ... Screening revenues, including laboratory service revenues from Cologuard and PreventionGenetics, totaled $544.9 million. The figure increased ...

Exact Sciences reports quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million miss the consensus estimate ...

Exact Sciences Corp ( (EXAS)) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its investors. Exact Sciences Corp. is a prominent company in ...

Exact Sciences' Q3 earnings report has led to a ~25% drop in its share price, due to a slight guidance cut and narrow revenue miss. Despite impressive historic revenue growth, Exact faces ...

Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.